- Home
- / Acerus Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Acerus Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Total Funding
$18 M
Revenue
($4.1 M)
FY, 2021
CreditSafe Score
?
Score changed on Jul 24, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
| Revenue | 7.4M | 3.8M | 1.1M | (4.1M) |
| Cost of goods sold | 1.5M | 514.0K | 501.0K | 307.0K |
| Gross profit | 5.9M | 3.3M | 770.0K | (4.3M) |
| Gross profit margin, % | 79.4% | 86.4% | 71.0% | 104.2% |
| Operating expense total | 17.8M | 13.3M | 21.0M | 27.0M |
| Depreciation and amortization | 4.6M | 3.7M | 1.0M | 2.3M |
| EBITDA | (12.0M) | (10.1M) | (20.2M) | (31.3M) |
| EBITDA margin, % | -162.2% | -267.1% | -1866.0% | 758.0% |
| EBIT | (16.3M) | (13.7M) | (21.2M) | (31.4M) |
| EBIT margin, % | -221.6% | -364.1% | -1952.2% | 759.8% |
| Interest income | 12.0K | 17.0K | 67.0K | 8.0K |
| Interest expense | 1.8M | 2.5M | 2.0M | 2.6M |
| Pre tax profit | (18.8M) | (16.1M) | (24.4M) | (33.8M) |
| Income tax expense | 29.0K | |||
| Net Income | (18.8M) | (16.1M) | (24.4M) | (33.8M) |